TN2014000421A1 - Methods of producing anamorelin hydrochloride having controlled chloride content - Google Patents

Methods of producing anamorelin hydrochloride having controlled chloride content

Info

Publication number
TN2014000421A1
TN2014000421A1 TN2014000421A TN2014000421A TN2014000421A1 TN 2014000421 A1 TN2014000421 A1 TN 2014000421A1 TN 2014000421 A TN2014000421 A TN 2014000421A TN 2014000421 A TN2014000421 A TN 2014000421A TN 2014000421 A1 TN2014000421 A1 TN 2014000421A1
Authority
TN
Tunisia
Prior art keywords
chloride content
methods
controlled chloride
anamorelin hydrochloride
producing
Prior art date
Application number
TN2014000421A
Other languages
English (en)
Inventor
Peter Manini
Shin-Itsu Kuwabe
Takehiko Yanagimachi
Hideyuki Yoshiyama
Groot Eleanor De
Rubio Silvina Garcia
Seemon Pines
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000421(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of TN2014000421A1 publication Critical patent/TN2014000421A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
TN2014000421A 2012-04-20 2014-10-08 Methods of producing anamorelin hydrochloride having controlled chloride content TN2014000421A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
PCT/US2013/037159 WO2013158874A1 (fr) 2012-04-20 2013-04-18 Procédés de production de chlorhydrate d'anamoréline présentant une teneur en chlorure régulée

Publications (1)

Publication Number Publication Date
TN2014000421A1 true TN2014000421A1 (en) 2016-03-30

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2014000421A TN2014000421A1 (en) 2012-04-20 2014-10-08 Methods of producing anamorelin hydrochloride having controlled chloride content

Country Status (47)

Country Link
US (8) US20140018391A1 (fr)
EP (3) EP2838892B1 (fr)
JP (3) JP6109925B2 (fr)
KR (2) KR102141323B1 (fr)
CN (3) CN110041304A (fr)
AP (1) AP2014008013A0 (fr)
AR (1) AR090725A1 (fr)
AU (1) AU2013249197B2 (fr)
BR (1) BR112014025972A8 (fr)
CA (2) CA2869893C (fr)
CL (1) CL2014002817A1 (fr)
CO (1) CO7131356A2 (fr)
CR (1) CR20140530A (fr)
CY (1) CY1120276T1 (fr)
DK (2) DK3517532T3 (fr)
DO (1) DOP2014000235A (fr)
EA (1) EA031581B1 (fr)
EC (1) ECSP14027739A (fr)
ES (2) ES2658862T3 (fr)
GE (1) GEP20186902B (fr)
HK (2) HK1202863A1 (fr)
HR (1) HRP20180316T1 (fr)
HU (2) HUE035697T2 (fr)
IL (1) IL235064B (fr)
JO (1) JO3353B1 (fr)
LT (1) LT2838892T (fr)
MA (1) MA37524B1 (fr)
MD (1) MD4615C1 (fr)
ME (1) ME02966B (fr)
MX (1) MX354793B (fr)
MY (1) MY170068A (fr)
NI (1) NI201400124A (fr)
NO (1) NO2877697T3 (fr)
NZ (1) NZ700833A (fr)
PE (1) PE20150084A1 (fr)
PH (1) PH12014502351A1 (fr)
PL (2) PL2838892T3 (fr)
PT (2) PT2838892T (fr)
RS (1) RS56869B1 (fr)
SG (2) SG10201608488RA (fr)
SI (2) SI2838892T1 (fr)
TN (1) TN2014000421A1 (fr)
TW (2) TWI589572B (fr)
UA (1) UA116207C2 (fr)
UY (1) UY34753A (fr)
WO (1) WO2013158874A1 (fr)
ZA (1) ZA201408508B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
DK3188599T3 (da) 2014-09-04 2019-11-25 Helsinn Healthcare Sa Medicinske behandlinger baseret på anamorelin
NZ736978A (en) 2015-07-24 2019-06-28 Newlink Genetics Corp Salts and prodrugs of 1-methyl-d-tryptophan
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
CN114630655A (zh) * 2019-08-30 2022-06-14 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
KR101324340B1 (ko) 2004-06-29 2013-10-31 헬신 세라퓨틱스 (유.에스.) 인크. (3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
TWI677494B (zh) 2019-11-21
US20160235804A1 (en) 2016-08-18
DK3517532T3 (da) 2022-01-03
CA2869893A1 (fr) 2013-10-24
EP3517532A1 (fr) 2019-07-31
MD20140122A2 (ro) 2015-05-31
PH12014502351B1 (en) 2015-01-12
EP2838892A1 (fr) 2015-02-25
TW201722928A (zh) 2017-07-01
CN110041304A (zh) 2019-07-23
JP6284665B2 (ja) 2018-02-28
SI3290410T1 (sl) 2020-11-30
NI201400124A (es) 2015-09-21
HRP20180316T1 (hr) 2018-04-06
GEP20186902B (en) 2018-10-25
ES2658862T3 (es) 2018-03-12
MY170068A (en) 2019-07-03
CL2014002817A1 (es) 2015-08-14
AU2013249197B2 (en) 2017-04-06
KR102141323B1 (ko) 2020-08-05
HK1202863A1 (en) 2015-10-09
CO7131356A2 (es) 2014-12-01
CA2869893C (fr) 2019-03-05
PT3517532T (pt) 2021-11-08
HK1248694A1 (zh) 2018-10-19
LT2838892T (lt) 2018-03-12
US10300105B2 (en) 2019-05-28
JP2017101082A (ja) 2017-06-08
ES2820354T3 (es) 2021-04-20
US20190231843A1 (en) 2019-08-01
CA3031652C (fr) 2020-10-27
MA37524A1 (fr) 2016-06-30
KR20190044697A (ko) 2019-04-30
AP2014008013A0 (en) 2014-10-31
TW201348224A (zh) 2013-12-01
PH12014502351A1 (en) 2015-01-12
MD4615B1 (ro) 2019-01-31
BR112014025972A2 (pt) 2017-06-27
JP2015514779A (ja) 2015-05-21
MX2014012178A (es) 2015-08-05
SG11201406478XA (en) 2014-11-27
US9956261B2 (en) 2018-05-01
CN110041398A (zh) 2019-07-23
EP2838892B1 (fr) 2017-12-06
PL2838892T3 (pl) 2018-05-30
US20190000914A1 (en) 2019-01-03
MD4615C1 (ro) 2019-08-31
JP6109925B2 (ja) 2017-04-05
US20200276259A1 (en) 2020-09-03
TWI589572B (zh) 2017-07-01
NZ700833A (en) 2016-01-29
EA031581B1 (ru) 2019-01-31
MX354793B (es) 2018-03-21
KR20150013115A (ko) 2015-02-04
SI2838892T1 (en) 2018-05-31
CN103857669B (zh) 2019-06-28
WO2013158874A1 (fr) 2013-10-24
RS56869B1 (sr) 2018-04-30
EA201401151A1 (ru) 2015-06-30
MA37524B1 (fr) 2017-04-28
CA3031652A1 (fr) 2013-10-24
EP3290410A1 (fr) 2018-03-07
US20140018391A1 (en) 2014-01-16
US9981002B2 (en) 2018-05-29
BR112014025972A8 (pt) 2021-06-22
ECSP14027739A (es) 2015-12-31
PL3290410T3 (pl) 2021-01-11
CR20140530A (es) 2015-03-25
PT2838892T (pt) 2018-02-28
ZA201408508B (en) 2020-01-29
CY1120276T1 (el) 2019-07-10
US20150072934A1 (en) 2015-03-12
HUE035697T2 (en) 2018-05-28
JO3353B1 (ar) 2019-03-13
DOP2014000235A (es) 2015-01-31
NO2877697T3 (fr) 2018-10-13
US20160237115A1 (en) 2016-08-18
CN103857669A (zh) 2014-06-11
EP3290410B1 (fr) 2020-07-01
DK2838892T3 (en) 2018-03-12
US10576122B2 (en) 2020-03-03
KR101972998B1 (ko) 2019-04-29
ME02966B (fr) 2018-07-20
US9872883B2 (en) 2018-01-23
SG10201608488RA (en) 2016-12-29
HUE050865T2 (hu) 2021-01-28
UY34753A (es) 2013-11-29
AR090725A1 (es) 2014-12-03
EP3517532B1 (fr) 2021-10-13
US9403867B2 (en) 2016-08-02
US20160229889A1 (en) 2016-08-11
AU2013249197A1 (en) 2014-10-30
US10905737B2 (en) 2021-02-02
JP6616853B2 (ja) 2019-12-04
PE20150084A1 (es) 2015-01-23
IL235064B (en) 2019-09-26
UA116207C2 (uk) 2018-02-26
IL235064A0 (en) 2014-12-31
JP2018076375A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
HK1198174A1 (en) Azeotrope-like compositions of e-1-chloro-2,3,3,3-tetrafluoropropene and uses thereof e-1--2333-
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
IN2014DN10386A (fr)
UA111186C2 (uk) Способи та композиції для одержання норибогаїну з воакангіну
PL2922893T3 (pl) Kompozycje utwardzane wilgocią, sposób ich wytwarzania i ich zastosowania
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
PH12014502351B1 (en) Methods of producing anamorelin hydrochloride having controlled chloride content
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2013164839A3 (fr) Forme amorphe d'apixaban, son procédé de préparation et compositions de celle-ci
IN2013MU03641A (fr)
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015016603A (es) Composiciones de corticosteroides.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
IN2013MU02777A (fr)
MY168958A (en) Intermediates and processes for preparing compounds
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.